Date of Report (Date of earliest event reported):
|
|
|
|
|
|
||||
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
||||
of Incorporation)
|
File Number)
|
Identification No.)
|
||||
|
|
|||||
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code
|
(
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on
which registered |
|
|
|
|
|
|
|
|
|
|
|
|
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
|
|||
By:
|
/s/ Kuk Hyoun Hwang | ||
Name:
|
Kuk Hyoun Hwang
|
||
Title:
|
Chief Executive Officer
|